Now Reading: New Medicine to Protect Higher-Risk Babies from RSV
-
01
New Medicine to Protect Higher-Risk Babies from RSV
Single injection to help prevent the common winter virus.
More babies who are born very prematurely will now be protected against the respiratory syncytial virus (RSV) with the introduction of a new single injection which lasts throughout the winter season.
Following advice from the Joint Committee on Vaccination and Immunisation (JCVI), the single dose long-acting antibody medicine, nirsevimab (Beyfortus®) will replace the five monthly jabs which were previously offered to higher-risk infants between October and February.
In addition, the existing programme for higher risk infants is being expanded to include very preterm infants, born before 32 weeks.
RSV can be life-threatening to babies born very early.
MINISTER FOR PUBLIC HEALTH JENNI MINTO
That is why I am pleased the single jab will be offered by all NHS Boards across Scotland from this September, helping to protect these high-risk infants over winter.
We will continue to work hard to protect Scotland’s most vulnerable groups against the respiratory illnesses which circulate throughout the colder months.
Our various prevention programmes help reduce avoidable admissions to hospital and therefore the pressure on our NHS.
The last year has seen significant progress in efforts to protect those most vulnerable to RSV, including the introduction of the maternal RSV vaccine which is offered at 28 weeks of pregnancy and helps protect newborn babies from serious illness.
DR SAM GHEBREHEWET, HEAD OF VACCINATION AND IMMUNISATION AT PUBLIC HEALTH SCOTLAND
Babies born prematurely are at highest risk of serious complications from RSV and we welcome this programme expansion, which will help to ensure that even more babies are protected during their most vulnerable early months.
Background
RSV can lead to life-threatening pneumonia and infant bronchiolitis, a lung infection.
The current RSV maternal vaccine (for infant protection) is given at 28 weeks, so the expansion of the programme to all infants born before 32 weeks gives protection to those babies who are unlikely to benefit from maternal vaccination.
The new injection for babies is the latest development in efforts to protect those most vulnerable to RSV and prevent unnecessary hospital admissions over the busy winter period. Last August, Scotland was the first nation in the UK to introduce another new RSV vaccine, Abrysvo, for pregnant women and older adults – more than 70% of eligible older adults took up the offer, leading to a Public Health Scotland study, published in the Lancet, showing a 62% reduction in RSV related hospitalisations among this group.
